Security key
H0036K147
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)
CUSIP: H0036K147
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Shares, par value CHF 0.08 per share
- Shares outstanding
- 128,459,465
- Total 13F shares
- 83,513,765
- Share change
- +1,276,593
- Total reported value
- $312,902,534
- Price per share
- $3.75
- Number of holders
- 118
- Value change
- +$4,946,064
- Number of buys
- 68
- Number of sells
- 42
Report period
Q1 2026
Institutions
118
Top holders
10
ADCT full security history
Previous quarter: Q4 2025
ADC Therapeutics SA SEC filings
ADC Therapeutics SA company facts
Broader feeds
Reporting periods
Holder history for CUSIP H0036K147
Recent filing periods:
Top shareholders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| HPWH TH AG |
13D/G
|
Dr. Hans-Peter Wild |
9.6%
|
9,788,944
|
$14,291,858 | $0 | 15 May 2025 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
9.2%
|
11,390,175
|
$42,143,648 | $0 | 27 Oct 2025 | |
| Prosight Management, LP |
13D/G
13F
|
Company |
6.8%
|
8,477,338
|
$31,366,151 | +$4,743,267 | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5%
from 13D/G
|
5,427,309
|
$19,158,401 | — | 31 Dec 2025 | |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
|
Oaktree Fund Administration, LLC |
4.1%
|
4,673,441
|
$18,693,764 | $0 | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
4%
|
5,014,617
|
$18,554,083 | -$10,422,190 | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company · ORBIMED CAPITAL LLC |
2.6%
from 13D/G
|
5,822,854
|
$20,554,675 | — | 31 Dec 2025 | |
| Jeremy Green |
3/4/5
|
10%+ Owner |
18%
|
22,932,028
|
$75,194,118 | -$19,636,340 | 31 Mar 2026 | |
| RedCo II Master Fund, L.P. |
3/4/5
|
10%+ Owner |
18%
|
22,932,028
|
$75,194,118 | -$19,636,340 | 31 Mar 2026 | |
| Hans Peter Wild |
3/4/5
|
10%+ Owner |
7.6%
|
9,788,944
|
$14,291,858 | — | 15 May 2025 | |
| Ameet Mallik |
3/4/5
|
Chief Executive Officer, Director |
1.6%
|
2,115,870
|
$8,315,191 | — | 13 Feb 2026 | |
| Jose Carmona |
3/4/5
|
Chief Financial Officer |
0.57%
|
734,376
|
$2,930,160 | — | 13 Feb 2026 | |
| Mohamed Zaki |
3/4/5
|
Chief Medical Officer |
0.53%
|
682,417
|
$2,722,843 | — | 13 Feb 2026 | |
| Peter J. Graham |
3/4/5
|
Chief Legal Officer |
0.48%
|
620,540
|
$2,475,954 | — | 13 Feb 2026 | |
| Peter Hug |
3/4/5
|
Director |
0.17%
|
220,500
|
$789,390 | — | 13 Jun 2025 | |
| Thomas Pfisterer |
3/4/5
|
Other* |
0.14%
|
173,899
|
$253,892 | — | 15 May 2025 | |
| Viviane Monges |
3/4/5
|
Director |
0.11%
|
144,043
|
$515,673 | — | 13 Jun 2025 | |
| Lisa Michelle Kallebo |
3/4/5
|
Chief Accounting Officer |
0.1%
|
128,224
|
$511,613 | — | 13 Feb 2026 | |
| Victor Sandor |
3/4/5
|
Director |
0.08%
|
108,286
|
$387,663 | — | 13 Jun 2025 | |
| Jean-Pierre Bizzari |
3/4/5
|
Director |
0.08%
|
106,902
|
$382,709 | — | 13 Jun 2025 | |
| Ron Squarer |
3/4/5
|
Director |
0.07%
|
93,627
|
$335,184 | — | 13 Jun 2025 | |
| Robert Azelby |
3/4/5
|
Director |
0.06%
|
80,405
|
$287,849 | — | 13 Jun 2025 | |
| Redmile Group, LLC |
3/4/5
13F
|
10%+ Owner · Company |
12%
from 13F
|
30,624,334
mixed-class rows
|
$105,194,110 | +$107,144,341 | 31 Mar 2026 | |
| TCG Crossover Management, LLC |
13F
|
Company |
8.9%
|
11,390,175
|
$40,207,318 | — | 31 Dec 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
4.3%
|
5,475,433
|
$19,328,279 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.9%
|
3,769,743
|
$13,307,192 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
2.6%
|
3,364,067
|
$11,875,157 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
1,640,872
|
$5,792,278 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.1%
|
1,407,325
|
$4,967,857 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1%
|
1,298,584
|
$4,584,002 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.88%
|
1,129,587
|
$3,987,442 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.78%
|
996,523
|
$3,517,725 | — | 31 Dec 2025 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
0.77%
|
990,778
|
$3,497,446 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.65%
|
830,903
|
$2,933,088 | — | 31 Dec 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.57%
|
733,568
|
$2,934,272 | — | 31 Dec 2025 | |
| Vantage Consulting Group Inc |
13F
|
Company |
0.53%
|
682,998
|
$2,410,983 | — | 31 Dec 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.46%
|
594,256
|
$2,097,724 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.41%
|
528,965
|
$1,860,000 | — | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.39%
|
502,570
|
$1,774,072 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.37%
|
471,693
|
$1,665,076 | — | 31 Dec 2025 | |
| Voleon Capital Management LP |
13F
|
Company |
0.36%
|
464,159
|
$1,638,481 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
437,551
|
$1,544,556 | — | 31 Dec 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.33%
|
418,782
|
$1,465,737 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.26%
|
328,429
|
$1,159,354 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.25%
|
320,048
|
$1,129,769 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.23%
|
298,218
|
$1,052,710 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.2%
|
263,071
|
$928,641 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.17%
|
215,212
|
$759,699 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.17%
|
212,915
|
$751,590 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.17%
|
212,668
|
$750,718 | — | 31 Dec 2025 |
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q1 2026
As of 31 Mar 2026,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
118 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
83,513,765 shares.
The largest 10 holders included
Redmile Group, LLC, TCG Crossover Management, LLC, Prosight Management, LP, BlackRock, Inc., EVENTIDE ASSET MANAGEMENT, LLC, Nantahala Capital Management, LLC, MORGAN STANLEY, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, and GOLDMAN SACHS GROUP INC.
This page lists
118
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
115
Q1 2026 holders
118
Holder diff
3
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.